Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.42 |
| ▸ | AGXT | P21549 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134778 | 0.79 | ALDH1A1 (0.41) | CYP3A4KCNH2MBOAT4GRM2GRM3 | |
| SCHEMBL1556910 | 0.77 | BACE1 (0.43) | IDO1AGXTCYP3A4KCNH2 | |
| SCHEMBL29100661 | 0.76 | ALDH1A1 (0.46) | CYP3A4MBOAT4GRM2GRM3TSHR | |
| SCHEMBL5313454 | 0.76 | CYP3A4 (0.40) | CYP3A4KCNH2MBOAT4GRM2GRM3 | |
| SCHEMBL5017655 | 0.76 | IDO1 (0.34) | IDO1AGXTCYP3A4KCNH2ALDH1A1 | |
| SCHEMBL904618 | 0.76 | — | — | |
| SCHEMBL31190859 | 0.76 | — | — | |
| SCHEMBL15856232 | 0.75 | KCNH2 (0.44) | IDO1AGXTCYP3A4KCNH2 | |
| SCHEMBL13141049 | 0.75 | IDO1 (0.42) | IDO1AGXTCYP3A4KCNH2MBOAT4 | |
| SCHEMBL22838148 | 0.75 | IDO1 (0.41) | IDO1AGXTCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885AGXT 3147/4885CYP3A4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.